KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Astrazeneca (AZN) Equity Average (2016 - 2025)

Astrazeneca has reported Equity Average over the past 10 years, most recently at $44.8 billion for Q4 2025.

  • Quarterly results put Equity Average at $44.8 billion for Q4 2025, up 11.94% from a year ago — trailing twelve months through Dec 2025 was $44.8 billion (up 11.94% YoY), and the annual figure for FY2025 was $44.8 billion, up 11.94%.
  • Equity Average for Q4 2025 was $44.8 billion at Astrazeneca, up from $40.0 billion in the prior quarter.
  • Over the last five years, Equity Average for AZN hit a ceiling of $44.8 billion in Q4 2025 and a floor of $27.5 billion in Q4 2021.
  • Median Equity Average over the past 5 years was $38.2 billion (2022), compared with a mean of $37.7 billion.
  • Biggest five-year swings in Equity Average: surged 81.67% in 2021 and later fell 0.16% in 2023.
  • Astrazeneca's Equity Average stood at $27.5 billion in 2021, then soared by 39.0% to $38.2 billion in 2022, then dropped by 0.16% to $38.1 billion in 2023, then rose by 5.0% to $40.0 billion in 2024, then increased by 11.94% to $44.8 billion in 2025.
  • The last three reported values for Equity Average were $44.8 billion (Q4 2025), $40.0 billion (Q4 2024), and $38.1 billion (Q4 2023) per Business Quant data.